Drug Trial Radar · NCT05750355
Evaluate the Effect of TPN171H on the QT/QTc Interval in Healthy Volunteers
Last checked: Nov 20, 2026Latest source record: Apr 5, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
32
Actual
Start
Oct 10, 2022
Primary completion
Dec 7, 2022
Study completion Dec 7, 2022
Sponsor
- Lead sponsor
- Vigonvita Life SciencesIndustry
- Sponsor type
- Industry
- First posted
- Mar 1, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a single-dose orally administered, dose-escalation, single-center, randomized, double-blind, placebo-parallel controlled clinical study evaluating the effect of TPN171H tablets on QT/QTc interval in healthy subjects.The main objective was to evaluate the effect of TPN171H tablets on QT/QTc interval in healthy Chinese subjects after a single oral administration.
Conditions
- Healthy Subjects
Interventions
TPN171H 10 mg GroupDrug
6 subjects will receive TPN171H 10 mg, orally; 2 subjects will receive placebo, orally.
TPN171H 30 mg GroupDrug
6 subjects will receive TPN171H 30 mg, orally; 2 subjects will receive placebo, orally.
TPN171H 40 mg GroupDrug
6 subjects will receive TPN171H 40 mg, orally; 2 subjects will receive placebo, orally.
TPN171H 50 mg GroupDrug
6 subjects will receive TPN171H 50 mg, orally; 2 subjects will receive placebo, orally.
Primary outcomes
What the sponsor says the trial is designed to measure.
- QT Interval Corrected Using Fridericia's FormulaTime frame: From Day 1 to Day3
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Huashan Hospital affiliated to Fudan University
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.